Hexarelin

Strictly for Research Purposes 

Disclaimer
Hexarelin peptide is available strictly for research and laboratory purposes only. It has not been approved by Health Canada and has not been evaluated for safety, efficacy, or quality. Unauthorized health products may pose serious health risks if used outside controlled research environments.

Hexarelin Peptide (Examorelin)

Description

Hexarelin (Examorelin) is a synthetic growth hormone–releasing peptide (GHRP) composed of six amino acids. It is structurally distinct yet functionally related to ghrelin, a 28–amino acid peptide known to stimulate growth hormone (GH) release and appetite. Hexarelin acts primarily through growth hormone secretagogue receptors (GHSR-1a) located in the pituitary and hypothalamus, initiating intracellular signaling cascades that may promote GH secretion.

Mechanism of Action

• Mimics ghrelin by binding to GHSR-1a receptors.
• Stimulates GH release via G-protein–mediated pathways (e.g., protein kinase C activation).
• May also influence appetite-regulating neuropeptides (NPY, AgRP) and reduce α-MSH, shifting balance toward increased hunger.
• Can transiently desensitize receptors with repeated exposure.
• May induce secretion of other pituitary hormones (ACTH, prolactin), though these effects are generally undesired in experimental contexts.

Chemical Properties

• • Molecular Formula: C47H58N12O6
  • Molecular Weight: 887.05 g/mol
  • Synonyms: Examorelin

Research Findings (Preclinical Models)

• • Growth Hormone Release: Hexarelin has been shown to elevate GH levels in adolescent and mature models, with variable effects in elderly groups.
  • Synergism with GHRH: Evidence suggests Hexarelin and GHRH act via distinct pathways, potentially producing additive GH stimulation when combined.
  • Cardiovascular Activity: Acute administration may enhance cardiac output, stroke volume, and left ventricular ejection fraction, while reducing apoptosis in ischemic heart tissue.
  • Body Composition: GH release following Hexarelin exposure appears inversely correlated with fat mass; sex differences were not significant.
  • Muscle Tissue Preservation: Preliminary studies indicate Hexarelin may reduce muscle mass and strength loss under catabolic conditions.
• Plain-Language Benefits (Research Context Only)

• Supports growth hormone release – may stimulate GH secretion in laboratory models.
• Cardiac effects – may improve heart function and protect cardiac cells in experimental studies.
• Muscle preservation – may reduce muscle loss under catabolic stress.
• Appetite regulation – may increase hunger signals and alter feeding behavior.
• Potential synergism – may complement GHRH activity for enhanced GH release.